

# Appendix 4E

## Preliminary Final Report Proteomics International Laboratories Ltd ABN 78 169 979 971

### Dates

|   |                                   |
|---|-----------------------------------|
| Financial Year Ended                    | 30 June 2017                      |
| Previous Corresponding Reporting Period | Financial year ended 30 June 2016 |

### Results for Announcement to the Market

|   | Current<br>Period<br>(30 Jun 2017)<br>\$ | Percentage<br>increase<br>/(decrease) over<br>previous<br>corresponding<br>period | Previous<br>Corresponding<br>Period<br>(30 Jun 2016)<br>\$ |
|---|--|---|--|
| Revenue from ordinary activities <sup>1</sup>                                     | 925,357                                  | 13.3%   | 816,845  |
| (Loss) from ordinary activities after tax<br>attributable to members <sup>2</sup> | (916,475)                                | (31.0%)   | (1,328,456)  |
| (Loss) for the period attributable to members                                     | (916,475)                                | (31.0%)   | (1,328,456)  |

#### Notes:

1. Revenue from continuing operations has been disclosed as revenue from ordinary activities.
2. Net loss for the period from continuing operations has been disclosed as loss from ordinary activities after tax attributable to members

| Dividends (distributions)  | Amount per security | Franked amount per security |
|--|---------------------|-----------------------------|
| Final Dividend   | Nil                 | Nil                         |
| Interim Dividend   | Nil                 | Nil                         |
| Record date for determining entitlements to the dividends (if any) | Not Applicable      |                             |

## Commentary on the results for the financial year ended 30 June 2017

**Brief explanation of any of the figures reported above necessary to enable the figures to be understood:**

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) presents this financial report for the year ended 30<sup>th</sup> June 2017, with the following explanation of the results:

- Operating revenue from services continued its upward trend reaching \$925,358, a 13% increase compared to the previous year.
- Revenue from ordinary activities encapsulates income from the Company's analytical services, licensing fees, and grant income including the R&D Tax Incentive.
- Proteomics International 's combined income from all sources rose 30% to \$1.86 million (2016: \$1.44 million).
- Operational expenditure remained steady at \$2.78 million (2016: \$2.76 million).
- The loss from ordinary activities is \$916,475 which represents a year on year decrease of 31%.
- At 30 June 2017 the Company had cash and security deposits of \$1.23 million. On the back of the Company's research and development focus it anticipates an R&D Tax Incentive cash rebate of \$790,751, to be received in the September quarter 2017.

A full description of Proteomics International's operational activities are contained in the Company's Annual Report for 2017 available here:

[www.proteomics.com.au/investors/reports-main-page/2017-annual-financial-reports/](http://www.proteomics.com.au/investors/reports-main-page/2017-annual-financial-reports/)

### Net tangible assets per ordinary share

|                              | 30 June 2017 | 30 June 2016 |
|------------------------------|--------------|--------------|
|                              | \$           | \$           |
| Net tangible asset per share | 0.03         | 0.02         |

### Details of Associates and Joint Venture Entities

|                           | Ownership Interest |           | Contribution to net profit/(loss) |             |
|---------------------------|--------------------|-----------|-----------------------------------|-------------|
|                           | 2017<br>%          | 2016<br>% | 2017<br>\$A                       | 2016<br>\$A |
|                           | N/A                | N/A       | N/A                               | N/A         |
| <b>Name of entity</b>     |                    |           |                                   |             |
| Associates                |                    |           |                                   |             |
| Joint Venture Entities    |                    |           |                                   |             |
| Aggregate Share of Losses |                    |           |                                   |             |

### Details of entities over which control has been gained or lost during the period

|                                    |     |
|------------------------------------|-----|
| <b>Name of entity</b>              | N/A |
| <b>Date of gaining control</b>     | N/A |
| <b>Commentary and contribution</b> | N/A |

### Audit Status

|  |                                     |  |                          |
|--|-------------------------------------|--|--------------------------|
| <b>This report is based on accounts to which one of the following applies:</b><br>(Tick one) |                                     |  |                          |
| The accounts have been audited   | <input checked="" type="checkbox"/> | The accounts have been subject to review           | <input type="checkbox"/> |
| The accounts are in the process of being audited or subject to review                        | <input type="checkbox"/>            | The accounts have not yet been audited or reviewed | <input type="checkbox"/> |

**If the accounts have not yet been audited and are likely to contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:**

Not applicable.

**If the accounts have been audited contain an independent audit report that is subject to a modified opinion, emphasis of matter or other matter paragraph, a description of the modified opinion, emphasis of matter or other matter:**

The independent audit report contains an emphasis of matter in relation to going concern. The emphasis of matter states that on the basis of the factors indicated in the going concern note to the financial statements, there is a material uncertainty that may cast significant doubt on the Companys ability to continue as a going concern and therefore, whether it will be able to realise its assets and discharge its liabilities in the normal course of business.